All protocols
GH / Growth Hormone

Tesamorelin Peptide Protocol & Dosing

Updated 1mo ago 6 min read 274+ helpful Calculator
Validity Score

Validity Score

73 Usable
Evidence 86
Community 70
Completeness 71
Actionability 80
Coverage 100
Penalty -8

This score combines formal evidence, page completeness, calculator readiness, and community convergence.

What it is

Tesamorelin is a synthetic GHRH analog used to reduce visceral adipose tissue, especially in HIV-associated lipodystrophy. It drives endogenous GH release rather than replacing GH directly.

Evidence boundary

Human trial evidence exists and the studied indication is clear. Keep the interpretation anchored to visceral fat and metabolic outcomes.

Trial evidence

  • PMID 42538058 — Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.
  • PMID 41545261 — Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.
  • PMID 41598480 — Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss.

Preparation and measurement

Reconstitution: 20 mg vial + 3 mL BAC = 6.67 mg/mL.

Concentration matches.

Reference schedule

Reference schedule
SettingDoseDraw / measureFrequencyWeekly total
Reference1 mg15 U (0.15 mL)Once daily7 mg/week
standard dose2 mg30 U (0.3 mL)Once daily14 mg/week

Reference

Dose
1 mg
Draw / measure
15 U (0.15 mL)
Frequency
Once daily
Weekly total
7 mg/week

standard dose

Dose
2 mg
Draw / measure
30 U (0.3 mL)
Frequency
Once daily
Weekly total
14 mg/week

Weekly totals apply only during the active phase. These are reference rows for the studied indication.

Titration rules

  • 1 mg/day is the cautious start.
  • 2 mg/day is the standard studied dose.
  • Keep the schedule tied to the HIV lipodystrophy indication.
  • Do not frame it as a generic fat-loss peptide.

Cycle length and breaks

Some protocols extend to 26 weeks or longer.

What to monitor

  • Visceral fat reduction
  • Liver fat and triglycerides
  • IGF-1 response
  • Fasting glucose and HbA1c
  • Injection-site reactions
  • Joint pain or edema

Practical rules

  • Keep it tied to the studied indication.
  • Avoid broad self-experiment framing.
  • Keep sleep and training solid.
  • Rotate sites.
Was this protocol helpful?
Share via

Related protocols

Sermorelin Peptide Protocol & DosingIpamorelin Peptide Protocol & DosingCJC-1295 (DAC) Peptide Protocol & DosingGHRP-2 Peptide Protocol & DosingTesamorelin + Ipamorelin Blend Protocol & Dosing

Dosing Calculator

10 mg + 2 mL BAC · suggested 1 mg
LIVE CALCULATIONvolume / concentration / draw
RP–CALC–01
DRAW AMOUNT20 units0.2 mL · U-100
Draw 20 units, equivalent to 0.2 milliliters.
Concentration5 mg/mL
Selected dose1 mg = 20 units
Enter a desired amount in milligrams or micrograms.
05 Standard doses
06 Suggested doses Select a row
1 unit = 0.01 mL on a U-100 syringe. Values retain decimal precision; visual marks are not silently snapped.
07 cycle summary

Vials required for Cycle

Estimate how much material you need for a full cycle, including cycle length and the number of cycles you plan to run.

Cycle total —
Total required vials —
Total reconstitution —
Total BAC water —